Search

Abdellah Joanna M Sentissi

from Dover, MA
Age ~75
Get Report
Also known as:
Abdellah Joanna Sentissi, Abdellah C Sentissi, Abdellah H Sentissi, Sentissi Abdellah, Sentissi Abdellam, Abella I
Phone and address:
1 High Rock Rd, Dover, MA 02030
(508) 785-2532
Related to:
Katie Maier
Connected to:
Cheryl L Sentivan, 76Jane A Sentivan, 79Chad A Sentle, 46Eric D Sentlinger, 48Rick W Sentlinger, 72Christopher Sentman, 41Eli S Sentman, 66Gary T Sentman, 64Geraldine D Sentman, 82Maureen F Sentman, 76

Abdellah Sentissi Phones & Addresses

  • 1 High Rock Rd, Dover, MA 02030 (508) 785-2532
  • Roxbury, MA
  • Newton Lower Falls, MA
  • 1 High Rock Rd, Dover, MA 02030

Work

Company: Rondaxe pharma Dec 2010 Address: Syracuse, New York Area Position: Senior quality advisor

Education

Degree: PhD School / High School: Northeastern University 1980 to 1985 Specialities: Biomedical sciences

Skills

Technology Transfer • Aseptic Processing • Change Control • Formulation • Gmp • Biotechnology • Capa • Fda • Validation • V&V • Biopharmaceuticals • Pharmaceutical Industry • Regulatory Affairs • Glp • Sop • Quality System • 21 Cfr Part 11 • Medical Devices • Lifesciences • Vaccines • Gxp • Gcp • Computer System Validation • Quality Assurance • Regulatory Submissions • Drug Discovery • Cro • Clinical Trials • Drug Development • Microbiology • Drug Delivery • Chemistry • Quality Control • Immunology • Oncology • Pharmacology • Assay Development • Life Sciences • Cell • Clinical Development • Standard Operating Procedure • Good Laboratory Practice • U.s. Food and Drug Administration

Languages

French • Arabic

Interests

Traveling • Soccer • Languages

Emails

a***[email protected]

Industries

Pharmaceuticals

Resumes

Resumes

Abdellah Sentissi Photo 1

Cmc And Qa-Qc Senior Consultant

View page
Location:
1 High Rock Rd, Dover, MA 02030
Industry:
Pharmaceuticals
Work:
Rondaxe Pharma - Syracuse, New York Area since Dec 2010
Senior Quality Advisor
Biotech and CROs since Aug 2008
Senior Consultant for QA and Manufacturing (GXP Consulting, LLC)
TransMolecular Nov 2005 - May 2010
VP of Manufacturing and Control
Biovest International May 2005 - Nov 2005
VP of Quality Systems
Diacrin/Genvec Oct 1995 - Apr 2004
VP of QA
Education:
Northeastern University 1980 - 1985
PhD, Biomedical sciences University of California, San Francisco 1977 - 1979
MS courses, Biomedical sciences Université Montpellier I 1976 - 1976
National Certification, Parasitology & Mycology Université Paul Sabatier (Toulouse III) 1968 - 1976
BS and national certifications, Pharmacy and Biomedical Sciences
Skills:
Technology Transfer
Aseptic Processing
Change Control
Formulation
Gmp
Biotechnology
Capa
Fda
Validation
V&V
Biopharmaceuticals
Pharmaceutical Industry
Regulatory Affairs
Glp
Sop
Quality System
21 Cfr Part 11
Medical Devices
Lifesciences
Vaccines
Gxp
Gcp
Computer System Validation
Quality Assurance
Regulatory Submissions
Drug Discovery
Cro
Clinical Trials
Drug Development
Microbiology
Drug Delivery
Chemistry
Quality Control
Immunology
Oncology
Pharmacology
Assay Development
Life Sciences
Cell
Clinical Development
Standard Operating Procedure
Good Laboratory Practice
U.s. Food and Drug Administration
Interests:
Traveling
Soccer
Languages
Languages:
French
Arabic

Business Records

Name / Title
Company / Classification
Phones & Addresses
Abdellah Sentissi
Manager
KINTAR SPORT HORSES, LLC
1 High Rock Rd, Dover, MA 02030
Abdellah Sentissi
Soc signatory
GXP CONSULTING LLC
1 Highrock Rd, Dover, MA 02030

Publications

Us Patents

Treatment Of Metastatic Tumors

View page
US Patent:
8227439, Jul 24, 2012
Filed:
May 15, 2009
Appl. No.:
12/466599
Inventors:
Alison O'Neill - Boston MA, US
Douglas B. Jacoby - Wellesley MA, US
Abdellah Sentissi - Dover MA, US
Kamala Kesavan - West Roxbury MA, US
E. Michael Egan - Brookline MA, US
Laura Sen, legal representative - Brookline MA, US
Assignee:
Morphotek, Inc. - Exton PA
International Classification:
A61K 48/00
A61K 38/00
A61K 38/16
A61K 35/00
US Classification:
514 44, 514 192, 424538
Abstract:
The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e. g. , intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.

Inhibition Of Angiogenesis

View page
US Patent:
8470607, Jun 25, 2013
Filed:
Sep 17, 2008
Appl. No.:
12/933638
Inventors:
Douglas B. Jacoby - Wellesley MA, US
Abdellah Sentissi - Dover MA, US
E. Michael Egan - Brookline MA, US
Kamala Kesavan - West Roxbury MA, US
Assignee:
Morphotek, Inc. - Exton PA
International Classification:
G01N 33/566
G01N 33/53
C12N 5/00
C07K 14/00
US Classification:
436501, 530300, 530324, 530350, 435 71, 435325
Abstract:
The present invention is directed to novel methods of inhibiting angiogenesis using chlorotoxin agents. In some embodiments, the inventive methods include intravenous, intraocular, intravitreal, subjunctival injection, and/or topical administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment and/or amelioration of ocular diseases characterized by neovascularization, such as wet macular degeneration. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.

Chlorotoxins As Drug Carriers

View page
US Patent:
20110091380, Apr 21, 2011
Filed:
Aug 7, 2008
Appl. No.:
12/672069
Inventors:
Douglas Jacoby - Wellesley MA, US
Abdellah Sentissi - Dover MA, US
E. Michael Egan - Brookline MA, US
Assignee:
TRANSMOLECULAR, INC. - Cambridge MA
International Classification:
A61K 51/08
C07K 14/435
C12N 9/96
A61K 38/17
A61P 35/00
A61K 38/43
A61K 31/7105
A61K 39/385
US Classification:
424 169, 530300, 435188, 530324, 530322, 514 193, 424 943, 514 44 A, 4241931
Abstract:
The present invention relates to the use of a toxin moiety (e.g., a chlorotoxin moiety) as a carrier for therapeutic agents, e.g., therapeutic agents that require intracellular uptake to exert their effects. For example, in some embodiments, the present invention provides conjugates comprising a toxin (e.g., a chlorotoxin) moiety and an anti-cancer moiety and methods for using such conjugates to increase cellular uptake and/or increase specificity for cancer cells of the anti-cancer drug. In some embodiments, the present invention provides conjugates comprising a toxin moiety (e.g., a chlorotoxin moiety) and a nucleic acid agent. Also provided are methods of treatment involving administration of such conjugates, and pharmaceutical compositions and kits useful for carrying out such methods of treatment.

Chlorotoxin Polypeptides And Conjugates And Uses Thereof

View page
US Patent:
20130028836, Jan 31, 2013
Filed:
Feb 4, 2011
Appl. No.:
13/577169
Inventors:
Abdellah Sentissi - Dover MA, US
Douglas B. Jacoby - Wellesley MA, US
Assignee:
MORPHOTEK, INC. - Exton PA
International Classification:
C07K 14/435
A61P 35/00
A61P 35/04
A61P 27/02
A61K 49/00
A61K 51/08
A61K 49/14
C12N 9/96
A61K 39/00
A61P 29/00
B82Y 5/00
US Classification:
424 169, 530325, 530324, 4241851, 424 96, 424 9341, 435188, 977774, 977927
Abstract:
Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.

Treatment Of Metastatic Tumors

View page
US Patent:
20130045163, Feb 21, 2013
Filed:
May 23, 2012
Appl. No.:
13/479203
Inventors:
Alison O'Neill - Cambridge MA, US
Douglas B. Jacoby - Wellesley MA, US
Abdellah Sentissi - Dover MA, US
Kamala Kesavan - West Roxbury MA, US
Laura Sen - Brookline MA, US
Assignee:
MORPHOTEK, INC. - EXTON PA
International Classification:
A61K 38/17
A61P 35/00
A61K 51/04
A61P 35/04
G01N 21/76
A61K 38/43
A61P 35/02
US Classification:
424 185, 424 941, 514 174, 435 75
Abstract:
The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.

Repetitive Hit-And-Run Immunoassay And Stable Support-Analyte Conjugates; Applied To T-2 Toxin

View page
US Patent:
48017264, Jan 31, 1989
Filed:
Apr 15, 1986
Appl. No.:
6/852144
Inventors:
Roger W. Giese - Quincy MA
Beverly Warden - Nashua NH
Allam Kariman - Dorchester MA
Markus Ehrat - Suhr, CH
Douglas J. Cecchini - Somerville MA
Abdellah Sentissi - West Roxbury MA
Assignee:
Northeastern University - Boston MA
International Classification:
C07F 710
US Classification:
556419
Abstract:
A repetitive immunoassay analytical method for determination of a free analyte is carried out by loading an affinity column of covalently bound analyte with tagged antibody, passing a continuous aqueous stream of carrier liquid over the column, introducing an aliquot of a sample to be analyzed for free analyte into the carrier stream upstream of the column, and monitoring the eluting carrier stream for a signal spike resulting from the presence of tagged antibody material released from the column by the application of free analyte in the analytical sample. Many samples may be analyzed by this method before the antibody-loaded affinity column needs to be regenerated. It is also disclosed that substrate-analyte conjugates of superior stability are produced by linking a substrate to a hydroxyalkyl analyte via an amino, hydrazide, or sulfide linking group replacing a hydroxy group. Such stable substrate-analyte conjugates are useful in the production and purification of antibodies, as well as in the repetitive immunoassay of the invention.

Novel Compositions And Methods For Treating Prostate Cancer

View page
US Patent:
20160002283, Jan 7, 2016
Filed:
Sep 15, 2015
Appl. No.:
14/854513
Inventors:
- Boston MA, US
Abdellah Sentissi - Dover MA, US
Richard Christian Moreton - Waltham MA, US
Mark Turnbull - Cambridge, CA
International Classification:
C07J 43/00
Abstract:
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. In some embodiments, the solid matrix comprises a polymer. In some embodiments, the polymer is soluble in an aqueous solution. In particular embodiments, the aqueous solution is water. In other embodiments, the aqueous solution has a pH of 5.0 or greater.

Treatment Of Metastatic Tumors

View page
US Patent:
20150374860, Dec 31, 2015
Filed:
May 4, 2015
Appl. No.:
14/702934
Inventors:
- EXTON PA, US
Douglas B. Jacoby - Wellesley MA, US
Abdellah Sentissi - Dover MA, US
Kamala Kesavan - West Roxbury MA, US
E. Michael Egan - Brookline MA, US
Laura Sen - Brookline MA, US
International Classification:
A61K 51/08
A61K 45/06
C12N 15/113
A61K 38/17
A61K 47/48
Abstract:
The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.
Control profile
Abdellah Joanna M Sentissi from Dover, MA, age ~75 Get Report